NVCR(NovoCure Limited) · 财务报表

NVCR(NovoCure Limited) 的财务报表:医疗保健,医疗器械。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$535.03M$537.84M$509.34M$605.22M$655.35M
毛利润$420.15M$422.97M$381.06M$468.04M$488.47M
营业利润−$44.33M−$89.52M−$232.87M−$170.50M−$153.80M
净利润−$58.35M−$92.53M−$207.04M−$168.63M−$136.23M
经营现金流$82.76M$30.79M−$73.34M−$26.37M−$49.03M
自由现金流$58.59M$9.43M−$100.43M−$69.22M−$75.68M
摊薄每股收益$-0.56$-0.88$-1.95$-1.56$-1.22

NovoCure Limited NVCR